Earnings Call · Q2 FY2024·2024-08-12

Q2 24EPS +70.59%·Rev n/aQ1 24EPS +100.00%*·Rev n/aQ4 23EPS -4.17%·Rev n/aQ3 23EPS +11.90%·Rev n/a⚠ consensus missing

Esperion Therapeutics, Inc. ESPR

Alina Venezia — Investor Relations

Sheldon Koenig — President and Chief Executive Officer

Ben Halladay — Chief Financial Officer

−8.9%1d on move date−9.0% vs SPY3d−7.9%5d−3.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ESPR calls or request research access.

More ESPR calls Browse calls Request research access